DeepMed Research

Pittsburgh Compound B

Generic Name: Pittsburgh Compound B

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂N_₂OS

CAS Number: 566170-04-5

Unique Ingredient Identifier: 7P55415B0R

Background: Pittsburgh Compound B is under investigation in clinical trial NCT01723553 (Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD).

Clinical Trials

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

Recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: [18F]Florbetazine ([18F]92)
Drug: [11C]PIB

First Posted Date: 2023-11-21

Last Posted Date: 2023-11-21

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 150

Registration Number: NCT06141356

Locations: 🇨🇳
Department of Nuclear Medicine, Peking Union Medical College Hopital, Beijing, China

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Conditions: Semantic Aphasia
PPA
PSP
LPA
Semantic Dementia
CBD
Parkinson Disease
PCA
Behavioral Variant of Frontotemporal Dementia
FTD

Interventions: Drug: C-11 PiB
Drug: AV1451 Tau
Drug: C-11 ER176

First Posted Date: 2020-12-22

Last Posted Date: 2024-11-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 500

Registration Number: NCT04680130

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

Terminated

Conditions: Alzheimer Disease
Healthy Aging

Interventions: Drug: 11C-PiB

First Posted Date: 2020-08-10

Last Posted Date: 2023-04-07

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 25

Registration Number: NCT04505735

Locations: 🇺🇸
University of Colorado, Denver, Aurora, Colorado, United States

11C-PIB PET Study in MESA at Columbia University

Completed

Conditions: Vascular Diseases
Atherosclerosis
Cognitive Impairment
Alzheimer Disease

Interventions: Drug: 11C-PIB

First Posted Date: 2019-06-10

Last Posted Date: 2025-02-18

Lead Sponsor: José A. Luchsinger

Target Recruit Count: 59

Registration Number: NCT03981380

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

Phase 1

Terminated

Conditions: Dementia

Interventions: Drug: 11C-ER176
Drug: 11C-PIB
Diagnostic Test: Positron Emission Tomography (PET) Scan

First Posted Date: 2019-05-22

Last Posted Date: 2024-05-01

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 13

Registration Number: NCT03958630

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Early Phase 1

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: 18F-MK-6240
Drug: 11C-PIB

First Posted Date: 2018-11-29

Last Posted Date: 2024-03-04

Lead Sponsor: José A. Luchsinger

Target Recruit Count: 5

Registration Number: NCT03757910

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

[C-11]PiB PET Imaging in Alcohol Use Disorders

Early Phase 1

Completed

Conditions: Alcohol Use Disorder

Interventions: Radiation: [C-11]
Drug: Pittsburgh Compound B

First Posted Date: 2018-11-19

Last Posted Date: 2024-12-13

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 39

Registration Number: NCT03746366

Locations: 🇺🇸
University of Pittsbyurgh PET Facility, Pittsburgh, Pennsylvania, United States

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Phase 2

Conditions: Parkinson Disease

Interventions: Drug: 11C-PiB

First Posted Date: 2018-06-13

Last Posted Date: 2018-06-13

Lead Sponsor: Oriental Neurosurgery Evidence-Based-Study Team

Target Recruit Count: 200

Registration Number: NCT03555292

Locations: 🇨🇳
Peking Tian Tan Hospital, Capital Medical University, Beijing, China
🇨🇳
Tianjin Huanhu Hospital, Tianjin, China
🇨🇳
Tianjin Medical University General Hospital, Tianjin, China

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Not Applicable

Recruiting

Conditions: Amnestic Mild Cognitive Disorder
Atypical Alzheimer's Disease
Amnestic Disorder
Alzheimer Disease
Alzheimer Disease, Early Onset
Logopenic Progressive Aphasia (LPA)
Posterior Cortical Atrophy (PCA)
Amnestic Symptoms

Interventions: Drug: F-18 AV 1451
Drug: C-11 PiB

First Posted Date: 2016-04-15

Last Posted Date: 2025-01-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 60

Registration Number: NCT02740634

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Florbetapir Calibration to the Centiloid Scale

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Florbetapir (18F)
Drug: 11C-PiB

First Posted Date: 2014-04-23

Last Posted Date: 2017-03-09

Lead Sponsor: Avid Radiopharmaceuticals

Target Recruit Count: 35

Registration Number: NCT02120664

Locations: 🇦🇺
Research Site, Heidelberg, Victoria, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy